A new perspective in pain management and opioid withdrawal relief
We are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment.
Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas."
PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.
A new perspective in pain management and opioid withdrawal relief
We are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment.
Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas."
PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.
Latest news
View all
PharmNovo at the LSX World Congress in London
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Congress in April 2025 in London. PharmNovo is redefining pain management with PN6047, a first-in-class Delta Opioid Receptor Agonist (DORA), safer, non-addictive solution for neuropathic pain. Unlike traditional opioids, PN6047 eliminates concerns of side effects, abuse potential, and tolerance. With a proven safety profile from Phase I trials and a market projected to exceed EUR 13 billion by 2033, PN6047 is set to be a game-changer.
Read more
Positive FDA feedback for PN6047
PharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia. Following a successful pre-IND meeting in January 2025, the FDA provided valuable guidance on the Phase IIa study design and had no critical comments on the CMC or non-clinical data. This paves the way for IND submission by the end of 2025 and a Phase IIa clinical trial application in Europe (Spain, Poland, Czech Republic) by Q3 2025.
Read more
Pioneering approach to treat neuropathic pain
PharmNovo has recently published an article in MedNous, highlighting the pioneering approach to tackling neuropathic pain without the risks traditionally associated with opioids. The lead candidate, PN6047, targets the delta-opioid receptor – offering pain relief without addiction or sedation. Arrangements for a Phase II trial have now been completed, marking a crucial step toward a safer alternative for millions suffering from chronic pain. With the opioid crisis still a major concern, innovative, non-addictive treatments like PN6047 are more urgent than ever.
Read more
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more